By Dr. Shipra Gandhi Roswell Park Comprehensive Cancer Center Endocrine therapy is the mainstay of the management of hormone receptor (HR) positive breast cancer. Until now, fulvestrant remained the only selective
Written by Dr. Chepsy Philip from Believers Church Medical College Hospital, Tiruvalla, Kerala, India KEYNOTE-087 is a multicentre, single-arm, multicohort, nonrandomized, phase 2 study of pembrolizumab in patients with R/R cHL who
More
X-7/7 trial: Alternative fixed dosing of capecitabine associated with similar efficacy with better safety profile By Drs. Arya Mariam Roy & Shipra Gandhi Roswell Park Comprehensive Cancer Center The approved
More
By Dr. Aakash Desai Mayo Clinic KEYNOTE-789: No Significant Efficacy Benefit with Addition of Pembrolizumab to Chemotherapy in TKI-Resistant, EGFR-Mutated Metastatic Nonsquamous NSCLC Key Points: The KEYNOTE-789 trial did not
More
By Dr. Luke Fletcher Willamette Valley Cancer Institute & Research Center Low-risk MDS had many exciting updates, starting with the COMMANDS trial. This study is an open-label randomized phase 3 trial
More
Palbociclib after progression on Palbociclib in HR-positive HER2-negative breast cancer does not show improvement in progression-free survival By Dr. Malak Alharbi of Roswell Park Comprehensive Cancer Center CDK4/6i plus endocrine
More
By Dr. Arya Miriam Roy & Dr. Shipra Gandhi of Roswell Park Comprehensive Cancer Center The CDK 4/6 inhibitors with endocrine therapy are the current standard of care for first-line treatment
More
Author: Lei Deng, MD PGY-6 Fellow Of Hematology/Oncology – Roswell Park Comprehensive Cancer Center, Buffalo, NY. Incoming Assistant Professor At UW/Fred Hutch, Seattle, WA Live report from ASCO23, Chicago, IL June 4, 2023
More
Author: Lei Deng, MD PGY-6 Fellow of Hematology/Oncology – Roswell Park Comprehensive Cancer Center, Buffalo, NY. Incoming Assistant Professor at UW/Fred Hutch, Seattle, WA Live report from ASCO23, Chicago, IL June 3, 2023 8am
More
By Dr. Chepsy Philip Believer’s Church Medical College Hospital Myeloproliferative – Chronic Myelomonocytic Leukemia (MP-CMML), a subset in the rare patient population of CMML, is associated with poor prognosis. Hydroxyurea (HY)
More
By Dr. Aditi Sharma of Barbara Ann Karmanos Cancer Institute & Dr. Abhishek Mangaonkar of Mayo Clinic In the longer-term follow-up of the phase III ASCEMBL trial published in Leukemia, Andreas
More